

Title (en)

TRANS-MEMBRANE-ANTIBODY INDUCED INHIBITION OF APOPTOSIS

Title (de)

TRANS-MEMBRAN-ANTIKÖRPER-INDUZIERTE APOPTOSE-HEMMUNG

Title (fr)

INHIBITION D'APOPTOSE INDUIITE PAR UN ANTICORPS TANSMEMBRANAIRE

Publication

EP 1605893 A4 20080813 (EN)

Application

EP 04718110 A 20040305

Priority

- US 2004006911 W 20040305
- US 45198003 P 20030305

Abstract (en)

[origin: WO2004078146A2] Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases.

IPC 1-7

C07K 16/00; C07K 16/28; A61K 39/395; A61K 39/44; A61K 51/10; G01N 33/533; G01N 33/541; G01N 33/554

IPC 8 full level

A61K 6/00 (2006.01); A61K 38/10 (2006.01); A61K 39/104 (2006.01); A61K 39/395 (2006.01); A61K 47/42 (2006.01); A61K 47/48 (2006.01); A61K 51/10 (2006.01); C07K 7/08 (2006.01); C07K 16/40 (2006.01); C07K 16/42 (2006.01); C07K 19/00 (2006.01); G01N 33/566 (2006.01)

IPC 8 main group level

A61K (2006.01)

CPC (source: EP KR)

A61K 39/395 (2013.01 - KR); A61P 31/04 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61P 31/18 (2017.12 - EP); A61P 35/00 (2017.12 - EP); C07K 16/00 (2013.01 - KR); C07K 16/40 (2013.01 - EP); C07K 16/426 (2013.01 - EP); A61K 2039/505 (2013.01 - EP); C07K 2317/76 (2013.01 - EP); C07K 2317/77 (2013.01 - EP); C07K 2319/00 (2013.01 - EP); C07K 2319/02 (2013.01 - EP)

Citation (search report)

- [X] WO 0160866 A1 20010823 - SECR DEFENCE [GB], et al
- [X] US 6316003 B1 20011113 - FRANKEL ALAN [US], et al
- [X] US 2002143142 A1 20021003 - LIN YAO-ZHONG [US], et al
- [E] EP 1488804 A1 20041222 - BIPHA CORP [JP]
- [X] STEIN S ET AL: "A disulfide conjugate between anti-tetanus antibodies and HIV (37-72)Tat neutralizes tetanus toxin inside chromaffin cells", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 458, no. 3, 24 September 1999 (1999-09-24), pages 383 - 386, XP004260296, ISSN: 0014-5793
- [A] ROJAS M ET AL: "GENETIC ENGINEERING OF PROTEINS WITH CELL MEMBRANE PERMEABILITY", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 16, no. 4, 1 April 1998 (1998-04-01), pages 370 - 375, XP001118371, ISSN: 1087-0156
- [T] ZHAO Y ET AL: "MTS-conjugated-antiactive caspase 3 antibodies inhibit actinomycin D-induced apoptosis.", APOPTOSIS : AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH DEC 2003, vol. 8, no. 6, December 2003 (2003-12-01), pages 631 - 637, XP002485667, ISSN: 1360-8185
- [T] MULLER SYBILLE ET AL: "TransMabs: cell-penetrating antibodies, the next generation", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 5, no. 2, 1 February 2005 (2005-02-01), pages 237 - 241, XP008093137, ISSN: 1471-2598
- See references of WO 2004078146A2

Cited by

US10435446B2; US10456475B2; US10654894B2; US11192922B2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2004078146 A2 20040916; WO 2004078146 A3 20060105; CA 2518119 A1 20040916; EP 1605893 A2 20051221; EP 1605893 A4 20080813; JP 2006522122 A 20060928; KR 20060006775 A 20060119

DOCDB simple family (application)

US 2004006911 W 20040305; CA 2518119 A 20040305; EP 04718110 A 20040305; JP 2006509211 A 20040305; KR 20057016454 A 20050905